Company Profile
Pulmonx Stock Price, News & Analysis
Company overview
Business overview
Pulmonx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Pulmonx is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Pulmonx follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Pulmonx sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
LUNG is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Pulmonx’s next three months are about Zephyr Valve adoption, new physician-site expansion, and continued lung-volume-reduction procedure growth. The company needs to keep proving that the minimally invasive COPD franchise can keep widening.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Pulmonx to Participate in September Investor Conferences
Source: Pulmonx
- 02
- 03
Pulmonx Reports Third Quarter 2025 Financial Results
Source: Pulmonx
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.